Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

克罗恩病，这个听起来似乎遥不可及的名字，却是许多人生活中的真实困扰。你是否听说过这种疾病，它不仅影响生活质量，还可能导致严重的身体不适？近年来，医药行业的发展给患者带来了希望，尤其是荃信生物-B（02509）近日获得的乌司奴单抗（Stelara®）对于克罗恩病的上市许可申请，无疑为患者的抗争铺就了一条新道路。 克罗恩病是一种慢性肠道炎症性疾病，患者通常经历腹痛、腹泻等令人难以忍受的症状。根据最新的 ...

根据公告，乌司奴单抗注射液是Stelara®的生物类似药，具有阻断IL-12和IL-23介导的信号传导的作用。该药物在全球的销售额在2024年达到了103.61亿美元，而在中国市场的销售额为7.39亿元人民币。公司在HDM3001（QX001S）项目 ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

2月12日，华东医药发布关于全资子公司收到药品注册受理通知书的公告。披露子公司杭州中美华东制药有限公司收到国家药品监督管理局（NMPA）签发的《受理通知书》，由中美华东申报的乌司奴单抗注射液（静脉输注）和乌司奴单抗注射液（研发代码：HDM3001-2/QX001S）用于克罗恩病的上市许可申请和补充申请获得受理。HDM3001（Q ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

HDM3001在克罗恩病这一新适应症的布局瞄准了持续增长的中国CD药物市场规模。公开资料显示，亚洲发病率虽然相比北美和西欧等发达国家较低，但呈明显的持续上升趋势。

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.